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Abstract
Background
Schistosoma infection is associated with immune modulation that can influence responses
to non-schistosome antigens. Vaccine responses may be impaired in S. mansoni-infected
individuals. We investigated effects of S. mansoni infection on responses to childhood mea-
sles catch-up immunisation and of praziquantel treatment on this outcome in a randomised
trial.
Methodology
The Immune Modulation and Childhood Immunisation (IMoChI) study was based in
Entebbe, Uganda. Children aged 3–5 years (193 S. mansoni-infected and 61 uninfected)
were enrolled. Infected children were randomised in a 1:1:1 ratio to receive praziquantel 2
weeks before, at time of, or 1 week after, measles catch-up immunisation. Plasma anti-mea-
sles IgG was measured at enrolment, 1 week and 24 weeks after measles immunisation.
Primary outcomes were IgG levels and percentage of participants with levels considered
protective against measles.
Results
Anti-measles IgG levels increased following immunisation, but at 1 week post-immunisation
S. mansoni-infected, compared to uninfected, children had lower levels of anti-measles IgG
(adjusted geometric mean ratio (aGMR) 0.4 [95% CI 0.2–0.7]) and the percentage with pro-
tective antibody levels was also lower (adjusted odds ratio 0.1 [0–0.9]). Among S. mansoni-
infected children, anti-measles IgG one week post-immunisation was higher among those
treated with praziquantel than among those who were not yet treated (treatment before
immunisation, aGMR 2.3 [1.5–4.8]; treatment at immunisation aGMR 1.8 [1.1–3.5]). At 24
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weeks post-immunisation, IgG levels did not differ between the trial groups, but tended to be
lower among previously-infected children who were still S mansoni stool-positive than
among those who became stool-negative.
Conclusions and significance
Our findings suggest that S. mansoni infection among pre-school children is associated with
a reduced antibody response to catch-up measles immunisation, and that praziquantel
treatment improves the response. S. mansoni infection may contribute to impaired vaccine
responses in endemic populations; effective schistosomiasis control may be beneficial for
vaccine efficacy. This should be further explored.
Trial registration
ISRCTN87107592.
Author summary
Infection with the blood fluke Schistosoma mansoni, which causes Bilharzia, is common
among communities living along the shores of Lake Victoria in Uganda and elsewhere
around fresh water bodies in Africa. Infection with this parasite is known to alter the
body’s immune responses, even to stimuli which are not directly related to the parasite.
This alteration may have an adverse impact on responses to vaccines. However, there is
still insufficient information on such effects and on whether treatment of schistosomiasis
can reverse them. We conducted a study on the Entebbe peninsula in Lake Victoria to
examine the effects of infection with S. mansoni parasites on responses to childhood mea-
sles catch-up immunisation, and the effect of treating the parasites on the responses. A
cohort of 3–5 year-old children, either infected with S. mansoni or not, was enrolled and
given measles immunisation. The infected children were treated for S. mansoni either
before, at the time of, or a week after the immunisation. Levels of antibodies against mea-
sles were measured at one week and 24 weeks after immunisation as indicator of possible
protection against measles. The levels of antibodies against measles were lower among the
S mansoni-infected children than the uninfected children, and treatment improved this
situation. This implies that S. mansoni infection is associated with reduced measles immu-
nisation responses and that treatment improves the response. At 24 weeks post-immuni-
sation, when all children had been treated for S. mansoni, at least 95% of children in all
groups had protective levels of antibody. Considering that pre-school children are vulner-
able to Bilharzia, an effective schistosomiasis control programme that includes this age
group may be beneficial for vaccine efficacy, an issue that needs further investigation.
Introduction
There is a striking geographical pattern in the efficacy of vaccines, some being less efficacious
in the tropics than in temperate regions. This has been particularly well documented with
regard to immunisation with BCG [1]. There is also evidence that the response to other vac-
cines, including those against measles, polio and typhoid, is sub-optimal in tropical regions
[2]. Among several hypotheses advanced to explain this phenomenon, one is that chronic,
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immunomodulating helminth infections, which are prevalent in the tropics, inhibit the devel-
opment of Th-type 1 immune responses required for protective immunity to many viral or
bacterial pathogens [3]. Despite considerable discussion of this hypothesis, studies to date have
largely examined effects on vaccines which are first given to young infants (such as BCG [4–8],
hepatitis B [9] and tetanus toxoid [6, 7, 10–13]), an age-group relatively unaffected by helminth
infections.
Measles immunisation is among vaccines that may have impaired responses in tropical
countries [2, 14]. It is usually first given at age nine months. In Entebbe, among infants immu-
nised against measles at age nine months at Entebbe Hospital, only 75% had “protective” anti-
body levels at age one year [15]. In a study among household contacts of measles patients in
Uganda, vaccine effectiveness was found to be only 74% [16]. Recent measles outbreaks in
Uganda have been associated, similarly, with evidence of low effectiveness of single-dose mea-
sles vaccine (70–75%) [17, 18] compared with other settings (median 84% for immunisation at
9 months, 92.5% for immunisation at 12 months) [19]. Catch-up and booster immunisation
on “child days” is offered in Uganda to address this problem. Low vaccine titres and poor vac-
cine handling have been suggested as explanations for the low effectiveness. The possibility of
a role of chronic helminth infection has not been widely explored [14].
Schistosoma mansoni infection is endemic in Uganda affecting mainly fishing communities
[20] including children under five years old [21–23]. S. mansoni infection is associated with
strong immunoregulation [24] and this has been shown to extend to unrelated antigens [25].
This might influence the responses to measles immunisations as a result of suppressed
responses due to impaired or altered antigen presentation [26], or a Th-type 2 biased response
[27, 28]. We hypothesised that immunogenicity to the measles vaccine is impaired in S. man-
soni infected children and that praziquantel treatment of S. mansoni infected children will
improve their responses to measles immunisation. Here we report findings of a study on the
association between S. mansoni infection and antibody responses to catch-up measles immuni-
sation among pre-school children, and of a randomised trial of the effect of praziquantel treat-
ment on the measles vaccine response–the first trial of this kind.
Methods
Ethics statement
Ethical approval of the study was obtained from the Uganda Virus Research Institute Science
and Ethics committee and the Uganda National Council for Science and Technology (HS
1307). Informed written consent was obtained from the parent or guardian of the children.
Study setting and enrolment of participants
We conducted an observational study combined with an individually randomised, non-
blinded, trial of praziquantel treatment for S. mansoni infection, investigating effects on the
response to measles immunisation (the “Immune Modulation and Childhood Immunisation”
study [IMoCh; registration number: ISRCTN87107592]). The study was based at the Uganda
Virus Research Institute, Entebbe, Uganda between February 2013 and March 2015 among
five fishing communities (Kigungu, Kasenyi, Rwanjaba, Bugonga and Nakiwogo) on the
Entebbe peninsula of Lake Victoria. Children, three to five years old, were screened for S. man-
soni infection, using the Kato-Katz technique [29] and a single stool sample. The screening
was done in collaboration with the Vector Control Division of the Ministry of Health, Uganda.
Children who were stool positive for S. mansoni were invited to participate in the study after
obtaining written informed consent from their parents or guardians.
Schistosoma mansoni and measles immunisation in pre-school children
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To obtain an S. mansoni uninfected comparison group, 85 children were randomly selected
from among stool negative children and also enrolled after obtaining written informed con-
sent from their parents or guardians. For this group, two additional stool samples were
requested on two consecutive days. Those found negative on all three stool samples were fur-
ther tested with S mansoni stool PCR, as previously described [30]. In brief, DNA from stored
stool was extracted using a QIAamp DNA Mini Kit (Qiagen), purified in QIAamp spin col-
umns, quantified on a Nano drop 2000c and diluted to 50ng/μl. Specific forward and reverse
primers and Taqman probes were used in a multiplex, real-time PCR. S. mansoni DNA was
detected using Ssp48F, Ssp124R and Ssp78T-TR with Texas Red and (BHQ2). Serial dilutions
of a positive pool were included to set a ct value cut off for the test samples. DNA amplifica-
tion, detection and data analysis were attained with the BIORAD CFX96 Real time system and
Bio-Rad CFX manager. Children found to be negative on all three stool samples and on PCR
were considered uninfected.
Randomisation and measles immunisation
Children infected with S. mansoni and enrolled into the study were randomly assigned in a
1:1:1 ratio to three study groups. Group A received praziquantel treatment (PZQ) two weeks
before measles immunisation, Group B received PZQ on the same day as measles immunisa-
tion, Group C received PZQ one week after measles immunisation (and after one-week blood
samples had been taken). PZQ treatment against S mansoni was by single-dose at 40 mg/kg in
accord with Ministry of Health guidelines. S. mansoni uninfected children (group D) received
measles immunisation but no praziquantel treatment.
A randomisation code was generated using a program in Stata (Stata SE version 11 Stata-
Corp, USA), by a statistician who did not participate in the clinical or laboratory work, and
delivered to the field workers in sealed envelopes. The field team allocated randomisation
numbers sequentially and treated participants according to the regimen indicated by the code.
Praziquantel (Cipla Ltd, Pantalgaanga M.S India) was provided by the Vector Control
Division.
Measles vaccine (1 ml single dose; Biofarma, Indonesia) was provided at Kigungu Health
Centre located in the study area.
Follow up of study participants and blood samples processing
Participants were followed-up at one week and 24 weeks after the measles immunisation. At
enrolment and at both follow-up time points, blood samples were drawn into heparin for
plasma. Plasma was stored at -80˚C until needed for assaying of anti-measles antibodies. At
the end of the study (24 weeks), children that still had evidence of patent worm infections were
treated accordingly.
Measurement of antibody responses to measles
Levels of measles-specific IgG in plasma were measured by the ELISA method, using a quanti-
tative commercial kit (Enzygnost anti-measles IgG kit OWLN155 & OUVP175, Siemens, Ger-
many) according to the manufacturer’s protocol and as previously described [15]. All three
blood samples taken at the different time points from the same individual were assayed on the
same plate; the sample sets from different individuals were randomised across the plates. The
IgG levels were quantified in milli-International units per millilitre of plasma (mIU/mL) calcu-
lated based on the formula: log10 mIU/mL = α x Aβ (where α and β are lot-dependent con-
stants provided by the manufacturer [31]). A protective response was defined as having a level
of measles-specific IgG greater than 200 mIU/mL as described by Naniche [32].
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Statistical methods
The primary outcome measures considered in this analysis were levels of measles-specific IgG
and percentage of children with IgG levels considered protective, measured at one week and at
24 weeks after measles immunisation.
Data analysis was performed with three main objectives: (1) at enrolment we assessed base-
line measles-specific IgG responses and associations with measles immunisation history, S.
mansoni infection, gender, and age; (2) at one week after measles immunisation we examined
for effect of S. mansoni infection on antibody responses by comparing IgG levels and propor-
tion with protective levels between stool negative children (group D) and S mansoni stool posi-
tive children who had not yet received praziquantel treatment (group C) in an observational
analysis, adjusting for baseline IgG levels and prior measles immunisation history; (3) at both
one week and 24 weeks after measles immunisation we examined for the effect of praziquantel
treatment timing among S. mansoni infected children on responses to measles immunisation
by comparing IgG levels between the three groups (A, B & C) who received praziquantel treat-
ment at different times with respect to the immunisation. Antibody data was skewed and was
log10 transformed. Unless otherwise stated, comparisons of antibody responses between and
within study groups were done by logistic regression (for the binary outcome) or by linear
regression (for the continuous outcome) with bootstrapping to generate 95% confidence inter-
vals. Log10 transformed data were back-transformed to express differences between groups as
geometric mean ratios.
Results
The study participants and baseline characteristics
One thousand and thirty-six children aged three to five years were screened, of whom, 252
(24%) were positive for S mansoni based on a single stool sample. All S. mansoni infected chil-
dren were invited to join the trial and 208 were enrolled but fifteen declined to have blood
drawn while fifteen children were subsequently excluded either due to failure to conform to
the treatment protocol (n = 12) or because they were later confirmed to be above the age of
five (n = 3), leaving 178 children for randomisation to the study groups. From the comparison
group of 85 stool negative children, 24 were excluded due to failure to provide additional stool
samples (n = 19) or PCR positive stool (n = 5) (Fig 1).
Of the 239 participants, 96.2% reported not to have had any previous praziquantel treat-
ment or other specific therapy against schistosomiasis. On the other hand, 172(72.0%) of the
children were reported to have had measles immunisation at age nine months and 153 (64.0%)
to have had measles immunisation during child health days’ campaigns in the past 12 months.
Of note 124/239 (51.9%) reported to have had immunisation at both 9 months and during
child health day campaigns in the past 12 months while 48/239 (20.1%) reported to have
received immunisation at 9 months only, 29/239 (12.1%) only had immunisation during child
health days and 38/239 (15.9%) reported to have never had any measles immunisation or were
not aware of having any. However, only 9.6% children provided immunisation cards, in con-
firmation of the immunisation record. For the rest we relied on the report from the parent or
guardian regarding immunisation history.
A summary of the baseline demographic characteristics of the study cohort is shown in
Table 1. Among the S. mansoni infected children, characteristics were similar between the
three randomised treatment groups except that group A (treated 2 weeks before immunisa-
tion) had somewhat lower pre-immunisation measles antibody levels.
Schistosoma mansoni and measles immunisation in pre-school children
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Baseline anti-measles IgG levels
At enrolment, we explored the baseline measles–specific IgG levels among the children and
examined possible associations with gender, reported immunisation history and infection with
S. mansoni. Overall, the geometric mean IgG level at enrolment was 1099 mIU/mL (95% CI
851, 1421) and 86.6% of the participants had antibody levels considered protective against
measles infection. As shown in Table 2, children with a history of previous measles immunisa-
tion had somewhat higher IgG levels (p = 0.05 for those immunised on child days). The base-
line antibody levels showed a tendency to be lower with increasing S. mansoni infection
intensity (p = 0.10). When adjusted for age, sex and the other variables in the model, the
adjusted estimates were similar to crude estimates. We therefore adjusted for prior measles
immunisation history and baseline measles antibody levels in subsequent analyses.
Association between S mansoni infection and anti-measles IgG response to
catch-up immunisation
Overall, and as expected, there was a significant boost in measles antibody levels following the
catch-up measles dose and this was seen for all study groups (Fig 2). The proportion with IgG
levels considered protective was 86.6%, 90.1% and 96.8% at enrolment, one week and 24 weeks
after immunisation respectively. Levels at 24 weeks after immunisation remained higher than
enrolment levels although among groups A and D, they had declined significantly, to levels
lower than those at one week after immunisation.
Fig 1. Flow diagram.
https://doi.org/10.1371/journal.pntd.0007157.g001
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Having observed a boost in antibody levels we wanted to examine whether S mansoni infec-
tion had an effect on the boost in antibody levels. To do this, we compared the anti-measles
IgG levels at one week between S. mansoni-infected children before their treatment (group C)
and uninfected children (group D). As shown in Table 3, one week post-immunisation levels
were lower in the infected than the uninfected children (p = 0.001). As well, the number of
children who had IgG levels below that considered protective at one week was more among
infected children (8/57, 14%) than among uninfected children (1/54, 2%) (Fishers exact
p = 0.03). For ethical reasons all S. mansoni infected children in group C were treated at one
Table 1. Baseline and demographic characteristics of the study cohort.
S mansoni stool positive children S mansoni stool negative
children
PZQ at two weeks before
immunisation (Group A)
PZQ at Immunisation
(Group B)
PZQ at a week after immunisation
(Group C)
(Group D)
N = 61 N = 58 N = 59 N = 61
Gender
Males 25(41%) 35(60%) 30(51%) 23(38%)
Females 36(59%) 23(40%) 29(49%) 38(62%)
Mean Age (years) 3.8(SD = 1.1) 3.9(SD = 0.8) 4.1(SD = 1.0) 4.0(SD = 0.8)
Other Worms
Trichuris trichiura 2(3.3%) 6(10.3%) 7(11.9%) 4(6.6%)
Hymenolepis nana 4(6.6%) 5(8.6%) 1(1.7%) 3(4.9%)
Ascaris 1(1.6%) 2(3.5%) 1(1.7%) 0
Hookworm 0 2(3.5%) 1(1.7%) 0
S mansoni intensity
Median epg (interquartile
range)
132 (36, 396) 60 (24, 222) 48(24,244)
WHO category
Light 29(47.5%) 34(58.6%) 40(67.8%)
Moderate 18(29.5%) 12(20.7%) 12(20.3%)
Heavy 14(23.0%) 12(20.7%) 7(11.9%)
Reported previous schistosomiasis treatment
Yes 2(3.3%) 4(6.9%) 1(1.7%) 1(1.6%)
Never 58(96.7%) 54(93.1%) 56(96.6%) 60(98.4%)
Not sure 0 0 1(1.7%) 0
Measles immunisation
At 9months
Yes 49(80.3%) 41(70.7%) 46(78.0%) 36(59.0%)
No 9(14.8%) 7(12.1%) 4(6.8%) 7(11.5%)
Not sure 3(4.9%) 10(17.2%) 9(15.2%) 18(29.5%)
At child days in last 12
months
Yes 33(54.1%) 40(69.0%) 38(64.4%) 42(68.9%)
No 24(39.3%) 10(17.2%) 16(27.1%) 11(18.0%)
Not sure 4(6.6%) 8(13.8%) 5(8.5%) 8(13.1%)
Anti-measles IgG at enrolment
Median IgG levels mIU/mL
(IQR)
818 (394, 2840) 1208 (521, 3406) 1090(579, 3962) 1277(438, 3832)
% with protective antibody
levels
52(85.3%) 50(86.2%) 51(87.9%) 53(86.9%)
https://doi.org/10.1371/journal.pntd.0007157.t001
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week after catch-up immunisation. At 24 weeks after catch-up immunisation, the IgG levels
were not significantly different between children who were infected or uninfected at enrol-
ment. At 24 weeks all the uninfected children (100%) had IgG levels considered protective
against measles while 95.7% of the children that were S mansoni positive at enrolment had lev-
els considered protective (Fishers exact p = 0.19).
Effect of praziquantel treatment of S mansoni on catch-up immunisation
anti-measles IgG levels
Having observed an association between S. mansoni infection and the anti-measles IgG
response, we next examined whether praziquantel treatment would have an effect on the anti-
body levels. This was done by comparing the IgG levels at one week as well as at 24 weeks after
immunisation between the three treatment groups as shown in Table 4.
At one week after catch-up immunisation, the percentage of children with IgG levels con-
sidered protective was over 85% in all the treatment groups and not significantly different
between the groups. IgG levels among the children who were treated with praziquantel either
before (group A) or at the time of catch-up immunisation (group B) were not significantly dif-
ferent, but were significantly higher than those of children who had not been treated (group
C) (Table 4; Fig 3). At week 24 there were no significant differences in the IgG levels between
Table 2. Crude associations between participant characteristics and anti-measles IgG levels at enrolment.
Geometric mean levels anti-measles IgG mUI/mL (95%
CI)
Geometric mean ratio
(95%CI)
% with protective antibody
levels
Odds Ratio (95% CI)
Gender
Boys (n = 113) 888 (617, 1276) 1 p = 0.11 84.10% 1 p = 0.29
Girls(n = 125) 1334 (928, 1918) 1.5 (0.9, 2.6) 88.80% 1.5 (0.7, 3.2)
Measles immunisation history
At 9 months b
Noc(n = 26) 1065 (423, 2685) 1 p = 0.94 80.80% 1 p = 0.28
Yes (n = 172) 1105 (827, 1478) 1.0 (0.4, 2.8) 88.40% 1.8 (0.6, 5.3)
Child days b
Noc (n = 61) 721 (402, 1293) 1 p = 0.05 83.60% 1 p = 0.19
Yes(n = 152) 1385 (1025, 1872) 1.9 (1.0,
3.5)
90.10% 1.8 (0.8, 4.2)
S. mansoni stool result
Negative(n = 61) 1312 (801, 2150) 1 p = 0.43 86.90% 1 p = 0.93
Infected
(n = 177)
1034 (764, 1399) 0.8 (0.5, 1.3) 86.40% 1.0 (0.4,
2.3);
S. mansoni intensity
Negative(n = 61) 1312 (801, 2150) 1 p = 0.10a 86.90% 1 p = 0.60
Light (n = 103) 1189 (800, 1769) 0.9 (0.5, 1.7) 88.40% 1.1 (0.4, 3.0)
Moderate
(n = 41)
1076 (564, 2051) 0.8 (0.3, 1.6) 87.80% 1.1 (0.3, 3.6)
Heavy (n = 33) 637 (309, 1313) 0.5 (0.2, 1.0) 78.80% 0.6 (0.2,
1.7)
Baseline measles IgG was missing for one child.
a Test for trend p value
b Parents/guardians were not sure of measles immunisation status at 9 months for 40 children, and on child days for 25 children.
c Note that children who had not received measles immunisation at 9 months may have received it on child days (reported for 14/26 cases), and those who had not
received on child days may have received at 9 months (reported for 39/61 cases)
https://doi.org/10.1371/journal.pntd.0007157.t002
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the three treatment groups or between the infected and treated groups and the uninfected
group D.
At 24 weeks’ follow-up, 72/138 (52%) of the children who were treated with praziquantel
were still S. mansoni stool positive. Of these children, antibody data was available for 134
Fig 2. Anti-measles IgG levels at respective time points for each treatment group. Group A received praziquantel (PZQ) 2 weeks before
measles immunization (MI), Group B received PZQ at the time of MI, Group C received PZQ one week after MI and Group D was S mansoni
negative and did not receive PZQ. Shown on the dot plots are medians with inter-quartile whiskers and the Wilcoxon Signed-rank paired sample
test p-values.
https://doi.org/10.1371/journal.pntd.0007157.g002
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participants (70 infected and 64 uninfected). We compared the IgG levels between the children
who were stool-positive and those who were stool-negative at the 24-week time point. The IgG
levels among children who were infected at enrolment, treated but still S. mansoni stool posi-
tive (GM 1805 (1242, 2624) mIU/ML) were lower than those who remained S. mansoni stool
negative (GM 2379 (1663, 3402) mIU/ML; aGM ratio 0.7 (0.4, 1.0) when adjusted for baseline
antibody levels, age and sex. The proportion of children with protective IgG levels was 65/70
(93%) among persistently stool positive compared to 63/64(98%) among those who became
stool negative (Fishers exact test, p = 0.13).
Discussion
This study explored the possible effects of S. mansoni infection on responses to measles catch-
up immunisation among three- to five-year-old children, and undertook the first trial to inves-
tigate the possible benefits of praziquantel treatment for a vaccine outcome. In an observa-
tional analysis we found that S. mansoni infection was associated with a reduced measles-
specific IgG response one week after measles catch-up immunisation and that S. mansoni-
infected children were less likely to develop IgG levels considered protective than their unin-
fected counterparts. In the trial we found that praziquantel treatment of S. mansoni infected
Table 3. Association of S mansoni infection with antibody levels one and 24 weeks following measles catch-up
immunisation.
S. mansoni status at
enrolment
Geometric mean levels of anti-measles IgG
mUI/mL (95% CI)
�Adjusted geometric mean
ratios (95%CI)
Responses at one week after immunisation
Uninfected (D, n = 54) 3949 (2661, 5859) 1
Infected (C, n = 57) 1401 (767, 2560) 0.4 (0.2, 0.7); p = 0.001
Responses at 24 week after immunisation
Uninfected (D, n = 51) 2184 (1477, 3230) 1
Infected at enrolment ((A, B,
C) n = 138)
2068 (1609, 2659) 1.1 (0.9, 1.5); p = 0.38
� Adjusted for child health days measles immunization history and baseline IgG levels.
https://doi.org/10.1371/journal.pntd.0007157.t003
Table 4. Effect of praziquantel treatment on antibody levels.
Timing of praziquantel (PZQ) treatment with respect to catch-up measles
immunisation (MI)
Geometric
means
GM ratios (95%
CI)�
% with protective
levels
Fisher’s Exact p
value
Levels at one week after the catch-up immunization
Not treated (C, n = 57) 1401 (767, 2560) 1 49 (86.0%)
Treated 2 weeks before MI (A, n = 51) 2233 (1214,
4104)
2.3 (1.4, 4.5) 45 (88.2%) 0.955
Treated at the time of MI (B, n = 49) 2339 (1282,
4267)
1.8 (1.1, 3.5) 43 (87.8%)
Levels at 24 weeks after the catch-up immunization
Treated one week after MI (C, n = 50) 2266 (1496,
3431)
1 48(96.0%)
Treated 2 weeks before MI (A, n = 46) 1858 (1205,
2863)
1.1 (0.7, 1.8) 44(95.7%) 1
Treated at the time of MI (B, n = 42) 2087 (1270,
3430)
1.0 (0.6, 1.6) 40(95.2%)
�Adjusted for baseline(enrolment) antibody level.
https://doi.org/10.1371/journal.pntd.0007157.t004
Schistosoma mansoni and measles immunisation in pre-school children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007157 February 14, 2019 10 / 17
children resulted in an improved measles-specific IgG response at one week post-immunisa-
tion when compared with those who were not treated. This study highlights the possible nega-
tive influence of S. mansoni infection on responses to immunisation and the beneficial effects
that treatment with praziquantel could offer.
In our relatively accessible Entebbe population, coverage of measles vaccine (85%), and
reported uptake of both 9-month and later child-day doses (over 50%), accorded with the
observed baseline proportion with protective antibody levels of greater than 85%. Although
measles immunisation in settings such as Uganda may result in protective antibody levels in
only three-quarters of the infants immunised [15], a second dose is expected to induce protec-
tive levels in 95% of recipients, providing protection for life [33]. This was achieved at 24
weeks for all groups in our study–in which all participants were treated for schistosomiasis
before this final endpoint. However, vaccine coverage is lower elsewhere in the country [17,
18]; as well, high prevalence of S. mansoni among pre-schoolers in endemic communities has
Fig 3. Measles specific IgG levels at one week after catch-up immunization. Error bars shown are median and
interquartile whiskers and Wilcoxon rank-sum (Mann-Whitney) test p-values.
https://doi.org/10.1371/journal.pntd.0007157.g003
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recently been reported from Uganda, with treatment of this group advocated [23] but not yet
widely practiced. Our results are consistent with the hypothesis that schistosomiasis contrib-
utes to impaired measles vaccine efficacy in Uganda (17, 18) although further investigation
among the affected communities would be needed to confirm this. While protective levels
against measles were indeed attained for most study participants in our study population, the
impact of schistosomiasis may be more important in populations with more marginal measles
vaccine coverage, and for vaccines that induce more marginal levels of protective immunity.
Helminth infections are associated with induction of an immunologically hyporesponsive
state [34] through modulation of innate or adaptive immune functions or both [24, 35, 36]. In
particular S. mansoni has been associated with modulation of antigen-presenting cell function
resulting in down-regulation or Th2 polarisation of the adaptive response [37, 38]. Active
Schistosoma infection is associated with elevated regulatory T cell (Treg) frequencies and sup-
pressed T cell responses to schistosome antigens, and this is alleviated or modified following
praziquantel treatment [39–41]. Treatment of schistosomiasis is also associated with changes
in circulating cytokine concentrations, such as a decline in circulating IL-10 [42]. The impact
of such treatment effects on responses to non-schistosome antigens has been little explored.
Our results suggest that there may be an immediate (but perhaps partial) alleviation of sup-
pressive effects on responses to unrelated antigens. As well as removing suppressive effects of
active, chronic Schistosoma infection, treating schistosomiasis is followed by an immediate
immunological “storm” due to the sudden release of adult worm antigen into the host circula-
tion, most marked in heavily infected people [43]: these changes could also impact the
response to an unrelated vaccine given concurrently.
The impact of S. mansoni and its treatment on the response at 24 weeks could not be deter-
mined from this study since all infected children had been treated by that time and the immu-
nological effects of treatment, discussed above, may have influenced the later evolution of the
measles-specific response. Of interest, the response in children treated after measles immuni-
sation (after sample collection at one week) was similar, by 24 weeks, to levels obtained in chil-
dren treated before or at immunisation. This suggests that the adverse effects of active S.
mansoni infection on antibody production can be alleviated by post-immunisation treatment.
This accords with a study of hepatitis B immunisation in S. japonicum infected mice: chroni-
cally Schistosoma-infected mice showed reduced antibody responses and Th2-biased cytokine
responses to the hepatitis vaccine antigen, but subsequent treatment with praziquantel resulted
in recovery of the antibody response and resolution of the Th2 bias [44]. Our observation that
children with persistent S. mansoni infection had inferior antibody levels at 24 weeks suggests
that more effective treatment (perhaps through optimised praziquantel dosing [45], or
repeated treatment) and avoidance of S. mansoni re-infection could deliver further improve-
ments in vaccine response.
We have recently reviewed previous studies on helminths and vaccine responses [46].
While studies in mouse models generally support the hypothesis that chronic helminth infec-
tion impairs responses to unrelated vaccines, studies in human populations have produced
variable results across a range of helminth species and vaccines. For S. mansoni several studies
in humans indicate an association with reduced antibody responses and, or, Th2 bias [12, 13,
47, 48]. For hepatitis B immunisation, adverse effects may be confined to individuals with
hepato-splenic schistosomiasis [49–51] or over-ridden by providing multiple doses [13]. Riner
and colleagues recently provided evidence that effects of S. mansoni co-infection on the
response to tetanus immunisation in young adults was greater among individuals with the
lowest pre-existing anti-tetanus antibody levels [13]. We recently found no evidence of an
effect of concurrent S. mansoni infection on the response to booster immunisation with the
investigational tuberculosis vaccine MVA85A (a live, non-replicating Modified Vaccinia
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Ankara vectored vaccine, expressing antigen 85A of Mycobacterium tuberculosis) among
Ugandan adolescents [52]. However, the participants had evidence of substantial prior expo-
sure to mycobacteria (in cellular and antibody responses to mycobacterial antigen, as well as
BCG scar) and S. mansoni infected participants showed a bias to IgG4 antigen 85A specific
antibody even before immunisation: perhaps repeated prior mycobacterial exposure domi-
nated the response to this vaccine, over-riding any effects of current S. mansoni co-infection.
This study on measles immunisation was the first to investigate the effects of Schistosoma coin-
fection on the response to a live, replicating attenuated viral vaccine. Such vaccines may be
particularly vulnerable to the effects of agents which modify the innate antiviral response and,
perhaps, limit vaccine replication [53, 54].
This study was of modest size and sampled participants at a limited number of time points:
assessing the antibody response at one week assumed that this would represent the peak of the
anamnestic anti-measles response but if some children had never received measles immunisa-
tion their peak may have been later. For ethical reasons we did not wish to leave children
untreated throughout follow up, limiting our ability to observe longer term effects. To be clas-
sified as uninfected children were required to have three samples negative for Schistosoma on
Kato Katz microscopy and one negative on PCR–a few of them may have had undetected, low
intensity infection. The main strength of the study was the trial design, allowing us to deter-
mine the effects of treatment, avoiding effects of confounding.
Conclusion
Our study provides evidence that active S. mansoni infection may have an adverse effect on
measles immunisation, and that treatment of S. mansoni with praziquantel may provide a ben-
efit which may be diminished by persistent infection or re-infection. The effects of S. mansoni
may be a factor contributing, among several others, to continued cases of measles reported in
Uganda and, more widely, to impaired responses to a range of vaccines in tropical settings.
There is need to confirm these results, to investigate further the direct impact of helminth
infections on responses to childhood, adolescent and adult immunisation, to determine the
categories of vaccine affected, and to evaluate the benefits for vaccine response that can be
achieved by interventions against helminth infections.
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